SAN FRANCISCO, Aug. 4, 2014 /PRNewswire/ -- Medizone
International, Inc. (The Company) (MZEI:QB, MZEI:OB)
announces excellent midpoint results from its new anti
viral research initiative in collaboration with a
world renowned virology institute.
"Medizone has now completed multiple decontamination runs with
well characterized samples of Adenovirus and MERS
Coronavirus," stated Dr Michael
Shannon, Medizone's President. "We are pleased to
announce that each run has shown 100% kill in a
full-scale room setting. Since all of the virology work has been
carried out by an internationally respected team of
virologists, we have complete confidence that these findings are
correct. By destroying both of these viruses, one a
non-enveloped virus and the second an enveloped Coronavirus, our
understanding of the biological limits for AsepticSureĀ® has been
expanded dramatically and of course so has the range of medical
applications."
Shannon went on to say: "Although still preliminary, we have
successfully achieved a 6 log kill with the Adenovirus and a 5.4
log kill with the Coronavirus. Efforts are continuing with the
Coronavirus to grow it in high enough concentrations to elucidate
AsepticSure's full decontamination capability with this deadly
virus. Once this work has been completed, we plan to shift our
focus to Norovirus, the plague of the seven seas."
Shannon continued about the importance of this work: "These new
findings should have intriguing implications for the management of
new deadly outbreaks world wide. Experts in this field have known
for years that bacterial spores and non enveloped viruses are at
the top of the biological resistance list for pathogens and we have
data by the truck load confirming that AsepticSure can achieve
100% kill of these pathogens at very high concentrations.
What is most exciting about these recent findings is that highly
lethal viruses such as Ebola should be extremely susceptible to
AsepticSure disinfection, which may therefore see AsepticSure
emerge as a vital component in global efforts to control these new
deadly outbreaks."
This Press Release may contain certain forward looking
statements that could involve substantial risks and uncertainties,
including, but not limited to, the results of ongoing clinical
studies, economic conditions, product and technology development,
production efficiencies, product demand, competitive products,
competitive environment, successful testing and government
regulatory issues. Additional risks are identified in the company's
filings made with the Securities and Exchange Commission.
Investor Relations, John
Pentony
T: (415) 331-0202
E: j.pentony@medizoneint.com
Media Contact, Gary Hanauer
T: (510) 686-1238
E: GarHan@aol.com
For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com
Photo - http://photos.prnewswire.com/prnh/20140803/132825
SOURCE Medizone International, Inc.